ArticleFrontiers in oncology2024

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring

Zeng-Hao Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.